Rank |
Status |
Study |
1 |
Recruiting
|
EScitalopram PIndolol ONset of Action
Condition: |
Unipolar Depression |
Interventions: |
Drug: escitalopram, pindolol; Drug: escitalopram |
Outcome Measures: |
MADRS score change between baseline and 2 weeks of treatment; Response/remission (MADRS) at 6 weeks; Adverse events; Correlation of drug level of pindolol and/or escitalopram and clinical outcome (primary outcome) between treatment groups |
|
2 |
Recruiting
|
Lexapro®'s Efficacy After Dose Escalation in Remission Study
Condition: |
Major Depressive Disorder |
Intervention: |
Drug: escitalopram |
Outcome Measures: |
Montgomery-Åsberg Depression Rating Scale (MADRS); Hamilton Depression Rating Scale-17 items (HAM-D); Hamilton Anxiety Rating Scale (HAM-A); Clinical Global Impression-severity (CGI-S); Clinical Global Impression-Improvement (CGI-I); Beck's Depression Inventory(BDI); WHO Quality Of Life scale Abbreviated Version(WHOQOL-BREF); Clinically Useful Depression Outcome Scale (CUDOS); Short From-36 Health survey (SF-36 Health survey) |
|
3 |
Unknown †
|
Circadian Effects of Escitalopram
Condition: |
Depression |
Intervention: |
Drug: placebo/escitalopram |
Outcome Measures: |
Resetting effect of Escitalopram on the circadian pacemaker; Correlation between improvement in depression with Escitalopram and the degree of realignment between the timing of sleep and the timing of the biological clock. |
|
4 |
Recruiting
|
Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
Conditions: |
Major Depressive Disorder; Major Depressive Disorder, Recurrent, Unspecified; Major Depressive Disorder, Single Episode, Unspecified |
Interventions: |
Drug: Escitalopram oxalate; Device: transcranial direct current stimulation |
Outcome Measures: |
Change in Hamilton Rating Scale for Depression, 17 items (HAMD17); Change in Montgomery-Asberg Depression Rating Scale (MADRS); Change in Beck Depression Inventory (BDI); Hamilton Rating Scale for Depression, 17 items (HAMD17) |
|
5 |
Recruiting
|
Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder
Conditions: |
Irritable Bowel Syndrome; Panic Disorder |
Intervention: |
Drug: Escitalopram |
Outcome Measures: |
Gastrointestinal Symptom Rating Scale (GSRS).; State Trait Anxiety Inventory (STAI). |
|
6 |
Unknown †
|
Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain
Conditions: |
Low Back Pain; Depression |
Interventions: |
Drug: Escitalopram; Drug: Placebo |
Outcome Measures: |
In comparison to placebo-treated patients, patients with treated with Cipralex report a significant reduction in depressive symptoms (>= 50% HAMD score) after 4 weeks of treatment.; In comparison to placebo, subjects treated with Cipralex report a significant reduction in pain intensity (>= 50% reduction of pain questionnaire score or VAS) after 12 weeks of treatment.; In comparison with placebo, subjects treated with Cipralex report a significant improvement in physical and everyday functioning after 12 weeks of treatment.; Personality traits do not have a significant influence on outcome regarding depressive traits, pain intensity and functioning.; Personality disorders are significantly influencing worse outcome regarding depressive traits, pain intensity and functioning. |
|
7 |
Recruiting
|
DECIFER: DEpression and Citalopram In First Episode Recovery
Conditions: |
Schizophrenia; Schizophreniform Disorder |
Interventions: |
Drug: Citalopram; Behavioral: Psychoeducation; Behavioral: Cognitive Behavioral Therapy (CBT); Radiation: Functional Magnetic Resonance Imaging (fMRI); Drug: Placebo |
Outcome Measures: |
Calgary Depression Scale for Schizophrenia (CDSS); Scale for the Assessment of Negative Symptoms (SANS); Brief Psychiatric Rating Scale (BPRS); InterSePT Scale for Suicidal Thinking (ISST); Heinrich Quality of Life Scale (QOL) |
|
8 |
Not yet recruiting
|
Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)
Condition: |
Major Depressive Disorder (MDD) |
Interventions: |
Drug: Agomelatine; Drug: Escitalopram |
Outcome Measures: |
Change from baseline in markers of sympathetic nervous system activity.; Change from baseline in the magnitude of morning surge in blood pressure.; To determine the association between sympathetic nervous system activity and left ventricular hypertrophy.; Change from baseline in insulin resistance.; Change from baseline on markers of cardiac risk. |
|
9 |
Unknown †
|
Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)
Condition: |
Major Depression |
Interventions: |
Drug: escitalopram; Drug: nortriptyline |
Outcome Measures: |
Hamilton depression rating scale; Drop out due to side-effects of drugs |
|
10 |
Recruiting
|
Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics
Condition: |
Alcohol Dependence |
Intervention: |
Drug: citalopram |
Outcome Measures: |
Craving for alcohol in type B alcohol dependence with citalopram compared to placebo; Striatal dopamine receptor availability in type B alcohol dependence with citalopram, compared to placebo |
|
11 |
Unknown †
|
The Effects of Escitalopram on Cytokines
Condition: |
Depression |
Intervention: |
Drug: Escitalopram |
Outcome Measures: |
The changes in cytokines; The changes in Hamilton Depression Rating Scale |
|
12 |
Recruiting
|
Brain Aging and Treatment Response in Geriatric Depression
Conditions: |
Mild Neurocognitive Disorder; MCI; Depression |
Interventions: |
Drug: Escitalopram; Drug: Memantine; Drug: Placebo |
Outcome Measures: |
Change in Hamilton Depression Rating Scale (HDRS) scores; Change in cognitive domain scores |
|
13 |
Unknown †
|
Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
Conditions: |
Depression; Continuous Antidepressant Abuse; Adverse Reaction to Drug |
Intervention: |
Drug: Escitalopram |
Outcome Measures: |
antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks; biological value at 0 week and 8 weeks |
|
14 |
Not yet recruiting
|
The ISLAND Study: InSuLa Assessed Needs for Depression
Condition: |
Depression |
Interventions: |
Drug: Escitalopram; Behavioral: Cognitive Behavioral Therapy; Other: Combination treatment (Escitalopram + CBT) |
Outcome Measures: |
Remission from major depressive episode; Response to treatment |
|
15 |
Unknown †
|
Citalopram for Cocaine Dependence
Condition: |
Cocaine Dependence |
Interventions: |
Drug: Citalopram; Drug: Placebo |
Outcome Measures: |
Abstinence; Cocaine Use Days; Cocaine-negative Urines; Retention in Treatment |
|
16 |
Recruiting
|
A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
Condition: |
Depressive Disorder, Major |
Intervention: |
Drug: Escitalopram |
Outcome Measures: |
Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF); Change From Baseline in Sheehan Disability Scale (SDS); Remission Rate at Week 8; Onset of Effect Rate at Week 1; Onset of Effect Rate at Week 2; Change From Baseline to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Scores; Change From Baseline to Week 8 in Hamilton Anxiety Scale (HAMA) Scores; Change From Baseline to Week 8 in Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) Scores |
|
17 |
Unknown †
|
Cipralex® for Anxiety Disorders in Adolescents
Condition: |
Anxiety Disorder |
Intervention: |
Drug: Cipralex® |
Outcome Measures: |
Treatment Efficacy; Physiological response to stress; Suicide risk |
|
18 |
Recruiting
|
Effects of Intravenous (IV) Citalopram on Emotional Brain Activity in Healthy Young and Elderly Adults
Condition: |
Healthy Young and Elderly Volunteers |
Interventions: |
Drug: Intravenous Citalopram; Drug: Normal Saline |
Outcome Measures: |
BOLD fMRI Response; Genetics and Cognitive/Emotional Change |
|
19 |
Unknown †
|
Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression
Condition: |
Chronic Depression |
Interventions: |
Other: CBASP psychotherapy; Drug: Escitalopram |
Outcome Measures: |
Depressive symptomatology after 8 weeks after randomization as measured by the MADRS; Depressive symptoms and remission 28 weeks after randomization; social, interpersonal and work function 28 weeks after randomization |
|
20 |
Unknown †
|
Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy
Condition: |
Marijuana Dependence |
Intervention: |
Drug: Escitalopram |
Outcome Measures: |
Clean urine THC samples; Questionnaire ratings of anxiety and depression and withdrawal symptoms |
|